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PURPOSE. The purpose of this study was to describe fundus autofluorescence (FAF) findings in
eyes with birdshot chorioretinitis (BSCR) and to compare findings to demographic, medical,
and clinical characteristics.
METHODS. In this multicenter, prospective, cross-sectional study, 172 eyes (86 patients) with
BSCR were investigated. Participants underwent a standardized evaluation including
collection of demographic data, ophthalmic and treatment history, and ophthalmologic
examination. Using a standardized protocol, hypo- and hyperautofluorescence in macular and
extramacular regions and specific patterns of abnormal FAF could be scored for 167 eyes.
Images were scored by two independent, masked graders. Measures of visual function
included best-corrected visual acuity (BCVA), contrast sensitivity (CS), color vision, and
Humphrey visual field mean deviation (HVF-MD).
RESULTS. Any abnormal FAF finding was observed in 132 eyes (79.0%); macular abnormalities
were observed in 84 eyes (49.1%). The most common findings were peripapillary confluent
hypoautofluorescence (122 eyes [73.1%]); extramacular granular hypoautofluorescence (100
eyes [59.9%]); and macular granular hypoautofluorescence (67 eyes [40.1%]). Confluent
hypoautofluorescence was related to longer median disease duration (8.7 years) than granular
hypoautofluorescence (7.9 years) or hyperautofluorescence (5.6 years). Macular confluent
hypoautofluorescence was associated with BCVA 20/25 (odds ratio [OR] ¼ 7.83, P ¼
0.007), BCVA 20/50 (OR ¼ 4.94, P ¼ 0.002), and abnormal CS (OR ¼ 4.56, P ¼ 0.009).
Presence of macular or extramacular hypoautofluorescence was related to HVF-MD 3 dB
(OR ¼ 2.43, P ¼ 0.01 and OR ¼ 2.89, P ¼ 0.003, respectively).
CONCLUSIONS. In this large cohort, various FAF abnormalities were found, indicating that
disorders of the retinal pigment epithelium are features of BSCR. Abnormal FAF is a marker of
visual dysfunction in the disease.
Keywords: birdshot chorioretinitis, fundus autofluorescence, retinal pigment epithelium
Birdshot chorioretinitis (BSCR), an autoimmune disease,affects the choroid, RPE, and retina. Imaging studies can
identify ocular abnormalities in eyes with BSCR that are not
apparent on clinical examination alone. In a study of 86
individuals with BSCR, we showed that enhanced depth
imaging optical coherence tomography (EDI-OCT) could
identify choroidal lesions that do not correspond to ‘‘birdshot
lesions’’ and are not apparent on examination of the fundus.1 In
other studies, fundus autofluorescence (FAF) imaging was also
able to show abnormalities not identified by clinical examina-
tion or other modalities.2–4
FAF identifies lipofuscin accumulation in the RPE and
provides information about RPE structure and health. Unmask-
ing of underlying RPE autofluorescence because of photore-
ceptor loss is an additional mechanism of hyperauto-
fluorescence.5,6 In eyes with BSCR, FAF imaging may demon-
strate RPE atrophy not corresponding to hypopigmented
birdshot lesions.2,3
Previous studies of FAF imaging and BSCR involved small
numbers of individuals, and they were primarily descriptive,
without extensive comparison to other disease features or
visual function.2–4 To expand our understanding of FAF in eyes
with BSCR, we performed a prospective study of FAF findings in
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the same cohort of 86 individuals whose choroids were studied
by EDI-OCT.1 As in that study, we compared imaging findings
to demographic and medical factors, clinical examination
findings, and multiple measures of visual function. Findings
may provide a better understanding of the spectrum of
abnormalities associated with BSCR, suggest disease mecha-
nisms, and identify features of the disease that should be
monitored in future clinical studies.
METHODS
Study Population
We recruited patients with BSCR at the following five
institutions for this prospective, cross-sectional study: Univer-
sity of California, Los Angeles (UCLA), Los Angeles, CA, USA;
Johns Hopkins University, Baltimore, MD, USA; Northwestern
University, Chicago, IL, USA; University of Utah, Salt Lake City,
UT, USA; and Duke University, Durham, NC, USA. All study
participants met criteria for the diagnosis of BSCR that were
established by an international group of investigators.7
Excluded were individuals with media opacities that precluded
imaging. Also excluded from the original cohort were
individuals with high myopia or hyperopia (spherical equiva-
lent >6 diopters [D]), AMD, or diabetic retinopathy, as these
conditions have been associated with choroidal abnormalities
on EDI-OCT (the subject of our initial study1).8–10 The study
was approved by the institutional review boards at each
clinical site, and written informed consent was obtained from
each study participant. The study adhered to the tenets of the
Declaration of Helsinki for research involving human subjects.
A detailed description of the cohort, data collection, and
study methods has been published.1 Briefly, all study partici-
pants underwent a standardized clinical examination, including
a series of visual function tests and imaging studies on a single
day. In addition, a questionnaire was administered at the study
visit to determine the presence or absence of eight prospec-
tively defined visual symptoms in each eye (blurry vision,
floaters, nyctalopia, poor contrast, abnormal color vision,
vibrating vision, metamorphopsia, and decreased peripheral
vision).11
Four measures of visual function were determined for each
eye. Best-corrected visual acuity (BCVA) was assessed using
Early Treatment of Diabetic Retinopathy Study (ETDRS) charts,
with manifest refraction. Color vision was assessed with the
Lanthony desaturated 15-hue color test12 and the confusion
index (C-index), as described by Vingrys and King-Smith,13 was
determined for each eye by entering study participant
responses into a web-based application available at http://
www.torok.info/colorvision/d15.htm (provided in the public
domain). The minimum possible score for C-index is 0.96, with
higher C-index values indicating poorer color vision; C-index
values of 1.78 or higher were considered abnormal. Contrast
sensitivity (CS) was measured using Pelli-Robson charts.14,15
The log of the CS measurement (logCS) was calculated and
used for analyses; logCS values <1.5 were considered
abnormal, as previously described.16 Automated perimetry
was performed using the 24-2 threshold program of the
Humphrey Field Analyzer (Carl Zeiss Meditec, Dublin, CA,
USA). Mean deviation (HVF-MD) scores were used in analyses;
values of 3.0 dB or less were considered abnormal.17,18
The following ophthalmologic variables were recorded:
intraocular pressure (IOP) determined by applanation tonom-
etry; anterior chamber cells by slit-lamp biomiscroscopy
(categorized according to Standardization of Uveitis Nomen-
clature [SUN] Working Group recommendations19); vitreous
inflammatory reactions (cells and haze, as described by
Nussenblatt et al.20); and fundus findings, including the
presence or absence of cystoid macular edema (CME) and
the presence or absence of retinal vasculitis. Information about
treatment with corticosteroids and immunomodulatory agents
(methotrexate, mycophenolate mofetil, azathioprine, cyclo-
sporine, tacrolimus, infliximab, and adalimumab) was record-
ed, as described previously.1 For study purposes, active disease
was defined as a vitreous haze score of ‡0.5þ. Presence of
CME was confirmed with OCT.
Image Acquisition Protocol and Image Evaluation
Autofluorescence was acquired with a standardized protocol
using the Spectralis HRAþOCT (Heidelberg Engineering,
Heidelberg, Germany) system, set at 558 with a minimal
automatic real time (ART) setting of 30. Included were a fovea-
centered FAF image and an optic disc-centered FAF image (Fig.
1). Two authors (CB and RFS), masked to clinical data, graded
the presence of autofluorescence abnormalities. Areas of
hypoautofluorescence were classified as being either confluent
or granular (Fig. 2). Confluent hypoautofluorescence was
defined as a round or oval area of absent autofluorescence
larger than 0.5 mm in largest linear diameter; granular
hypoautofluorescence was defined as a round or oval area of
decreased, nonhomogeneous autofluorescence, compared
with normal surrounding areas, that was greater than 0.5 mm
in largest linear diameter. All areas of hyperautofluorescence
greater than 0.5 mm in greatest diameter had a granular
appearance. Isolated FAF abnormalities smaller than 0.5 mm in
diameter were considered to be not clinically relevant and
were not recorded. For the purposes of these analyses, global
hypo- and hyperautofluorescence were defined as the pres-
ence of any hypo- and hyperautofluorescence, respectively,
located in macular or extramacular locations. For each eye,
disagreement between the two readers were adjudicated
before recording of data.
During evaluation of the fovea-centered image, the ETDRS
macular grid was used to identify three areas: within the
central 1-mm circle (termed central circle), between the 1- and
6-mm circle (termed pericentral-macular ring), and extramac-
ular (outside the 6-mm circle, including both the macular and
disc-centered scans). Hypo- and hyperautofluorescence were
graded separately for each area. For purposes of analysis, the
macula was the combined areas of the pericentral-macular ring
and the central circle.
FIGURE 1. Normal fundus autofluorescence images showing protocol
settings. A fovea-centered image (A) shows areas of analysis, including
foveal region (inside the central [inner] circle); pericentral-macular ring
(between the inner and outer circles), and extramacular area (outside
the outer circle); for purposes of analyses, the macular region included
the combined areas of the pericentral-macular ring and the central
circle. A optic disc–centered image (B) allowed analysis of the
peripapillary region of the fundus. Findings on the optic disc–centered
image were included in all analyses of the extramacular region.
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The graders also identified the presence or absence of
multiple patterns of FAF that have been described previous-
ly.2,3,21 When confluent hypoautofluorescence existed in the
area within 1 disc diameter from the optic disc, it was cate-
gorized as the pattern of peripapillary confluent hypoauto-
fluorescence. The perivascular pattern (Fig. 3) was a
distribution of hypo- or hyperautofluorescence that followed
the retinal vessels. A descending tract (Fig. 3) was a downward
leading swathe of hypoautofluorescence originating from the
posterior pole to extend below the level of the inferior arcade,
as described previously.21 We also identified an additional
distinct pattern, not described previously, but present in many
participant eyes with BSCR that we termed the arcuate pattern
(Fig. 3); it was characterized by a curved distribution of
hypoautofluorescence that was present superior and inferior
to the disc and that was typically sharply delineated.
Data Analyses and Statistical Techniques
Characteristics and patterns of FAF findings were quantified,
and relationships between various characteristics were inves-
tigated. FAF findings were compared with demographics,
disease duration, treatment, signs of intraocular inflammation
on clinical examination, and findings on EDI-OCT. Percentages
were calculated for categorical variables. Means with SDs and
FIGURE 2. Fundus photographs and autofluorescence images of eyes
with BSCR. (A) Example of combined confluent (arrow) and granular
hypoautofluorescence (white arrowhead); note that there is also
subtle granular hyperautofluorescence (blue arrowhead). (B) Example
of extensive granular hypoautofluorescence (white arrowhead) with
foveal sparing; the fundus photograph of the same eye shows only
subtle pigmentary changes in the posterior pole. (C) Example of
granular hyperautofluorescence (blue arrowheads); the fundus
photograph of the same eye does not show obvious abnormalities.
FIGURE 3. Fundus photographs and autofluorescence images showing
fundus autofluorescence patterns in eyes with BSCR. (A, B) Examples
of the perivascular pattern. Note in A that the hypoautofluorescent
dots are distributed along the retinal vessels (arrow). Note in B that the
hypoautofluorescent dots are distributed along both larger and smaller
retinal vessels (arrows). (C) Example of the arcuate pattern;
hypoautofluorescence is present in a curved distribution superior
and inferior to the disc, whereas unaffected RPE is sharply delineated
(white arrowheads). (D) Example of the descending tract pattern; the
downward leading swathe of decreased autofluorescence originates
from the posterior pole and extends below the level of the inferior
arcade (blue arrowhead). All examples also exhibit confluent
peripapillary hypoautofluorescence, a very frequent finding in eyes
with BSCR.
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median values with interquartile range (IQR) were calculated
for continuous variables. The associations between FAF
findings and clinical data were evaluated using logistic
regression, and odds ratios (ORs) were reported. Both crude
and adjusted ORs were calculated using logistic regression
models that incorporated generalizations of generalized esti-
mating equations to account for any correlation between eyes
of an individual patient.22 P values for all analyses were
nominal, with a value of <0.05 considered statistically
significant. All statistical analyses were performed with
Intercooled Stata SE 12.0 (Stata Corp LP, College Station, TX,
USA).
Analyses involving choroidal findings for this cohort have
been published previously.1 Evaluation of retinal OCT image
findings will be reported in a subsequent publication.
RESULTS
Included in the study were 172 affected eyes of 86 individuals
with BSCR. Study design and demographic, medical, and
clinical data for the cohort were described in a previous
publication.1 Briefly, median age of participants was 56 years
(IQR, 51–64 years); 54 (63%) were female; and each of 83
participants tested were HLA-A29 positive. Median disease
duration was 5 years. Disease was active (‡0.5þ vitreous haze)
in 50 (29%) eyes, and CME was present in 38 (22%) eyes at the
study visit. Median BCVA at the study visit was 20/25. Median
logCS was 1.5 (IQR, 1.35–1.65); 51 eyes (35%) had abnormal
CS. Median color index was 2.4; 70 eyes (69%) had abnormal
color vision results. Median HVF-MD was3.5 dB (IQR,9.4 to
1.8 dB); 79 eyes (55%) had an abnormal visual field result.
BCVA was 20/20 or better in 74 (42%) eyes; among these eyes,
40 (54%) had abnormal color vision, 17 (23%) had abnormal
HVF-MD, and 7 (10%) had abnormal CS.1
FAF images were missing for 5 eyes (five study participants),
leaving 167 eyes for analysis. An abnormal FAF finding was
observed in 132 eyes (79.0%); macular abnormalities were
observed in 82 eyes (49.1%). Table 1 summarizes FAF findings
by pattern and region. Four patterns were identified: perivas-
cular, arcuate, descending tract, and peripapillary confluent
hypoautofluorescence. The most common findings were
confluent peripapillary hypoautofluorescence (122 eyes
[73.1%]), extramacular granular hypoautofluorescence (100
eyes [59.9%]), and macular granular hypoautofluorescence (67
eyes [40.1%]). In the central circle, 6 (3.6%) eyes of 4 study
participants had confluent hypoautofluorescence and 22
(13.2%) eyes of 15 study participants had granular hypoauto-
fluorescence, but no eyes had hyperautofluorescence in this
region. The proportion of eyes having each type of FAF
abnormality increased as regions became more peripheral (i.e.,
from central circle to pericentral-macular ring to extramacular
regions); however, specifically with regard to confluent
hypoautofluorescence, the effect was small, and the trend
was not statistically significant.
Of 82 eyes with any FAF abnormality in the macula, 76
(92.5%) also had extramacular FAF abnormalities. There were
77 (46.1%) eyes with hyperautofluorescence in any anatomic
location (global hyperautofluorescence) and 132 (79.0%) eyes
with hypoautofluorescence in any anatomic location (global
hypoautofluorescence). FAF findings were asymmetric be-
tween eyes of many study participants; 51 (30.5%) eyes of 34
patients (39.5%) had normal FAF images in at least one eye.
FAF images were normal in both eyes of 20 (23.2%) study
participants.
Table 2 summarizes relationships between demographic
and treatment variables and FAF findings. Increasing age and
duration of disease were significantly associated with the
presence of global hypoautofluorescence and with the
presence of peripapillary confluent hypoautofluorescence.
Study participants with confluent hypoautofluorescence had
longer disease duration (median, 8.7 years) than patients with
granular hypoautofluorescence (median, 7.9 years) or those
with granular hyperautofluorescence (median, 5.6 years).
Those with normal autofluorescence in both eyes had the
shortest duration of disease (median, 2.3 years; P for trend <
0.001). Study participants using systemic corticosteroids at
the study visit were more likely to have global hypoauto-
fluorescence (OR ¼ 2.37, P ¼ 0.009); those receiving
immunomodulatory therapy had lower odds of having FAF
abnormalities in general, but none of the associations
achieved statistical significance. Multivariable analyses con-
trolling for demographic characteristics and signs of intraoc-
ular inflammation did not reveal statistically significant
associations between immunomodulatory therapy and FAF
abnormalities, with one exception: it was associated with a
lower odds of having the descending tract pattern (OR¼0.30,
P ¼ 0.02).
Table 3 summarizes relationships between signs of intraoc-
ular inflammation and FAF findings. Presence of retinal
vasculitis was associated with peripapillary confluent hypo-
autofluorescence (OR¼ 4.30, P < 0.001), and macular edema
was associated with global hypoautofluorescence (OR ¼ 5.26,
P < 0.001). Although vitreous haze was not significantly
TABLE 1. Fundus Autofluorescence Findings for 167 Eyes of 86
Individuals With BSCR
Autofluorescence Finding
Study
Participants*,
n ¼ 86
Eyes,
n ¼ 167
Patterns, n (percentage)
Perivascular pattern 30 (34.9%) 48 (28.4%)
Arcuate pattern 26 (30.2%) 44 (26.4%)
Descending tracts 16 (18.5%) 25 (14.8%)
Peripapillary confluent
hypoautofluorescence
66 (76.7%) 122 (73.1%)
Areas, n (percentage)
Central circle†
Normal autofluorescence 80 (93.0%) 143 (85.6%)
Confluent hypoautofluorescence 4 (4.7%) 6 (3.6%)
Granular hypoautofluorescence 15 (17.4%) 22 (13.2%)
Granular hyperautofluorescence 0 0
Pericentral-macular ring‡
Normal autofluorescence 56 (65.1%) 85 (50.9%)
Confluent hypoautofluorescence 14 (16.3%) 19 (11.4%)
Granular hypoautofluorescence 42 (48.8%) 67 (40.1%)
Granular hyperautofluorescence 16 (18.6%) 23 (13.8%)
Extramacular region§
Normal autofluorescence 32 (37.2%) 55 (32.9%)
Confluent hypoautofluorescence 24 (27.9%) 33 (19.8%)
Granular hypoautofluorescence 56 (65.1%) 100 (59.9%)
Granular hyperautofluorescence 30 (34.9%) 46 (27.5%)
* Participants with findings in at least one eye.
† Central Circle was defined as the area within 1 mm of the
geometric center of the fovea.
‡ The pericentral-macular ring was defined as the area extending
from the outer border of the central circle to 3 mm from the geometric
center of the fovea.
§ The extramacular region was defined as the area peripheral to the
pericentral-macular ring (greater than 3 mm from the geometric center
of the fovea) and captured on the fovea-centered fundus autofluores-
cence image and the area captured on the disc-centered fundus
autofluorescence image.
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associated with any FAF abnormalities, the presence of vitreous
cells (‡0.5þ) was associated with global hyperautofluores-
cence (OR ¼ 2.14, P ¼ 0.04) and the arcuate (OR ¼ 3.41, P ¼
0.003) and descending tract (OR ¼ 2.24, P ¼ 0.04) patterns.
Associations between vitreous cells and perivascular (OR ¼
1.93, P ¼ 0.07) and peripapillary confluent hypoautofluor-
escence (OR ¼ 2.30, P ¼ 0.08) patterns were of borderline
significance. Multivariable analyses controlling for demograph-
ic and treatment variables yielded similar results (data not
shown).
Comparisons between the choroidal findings described in
our previous publication about this cohort,1 and current FAF
findings revealed only that thin choroids were associated
with the presence of global hypoautofluorescence (P ¼
0.002) and peripapillary confluent hypoautofluorescence (P
< 0.001). Macular choroidal lesions were not significantly
related to macular FAF abnormalities (P > 0.05 for all
comparisons).
Tables 4 and 5 summarize relationships between measures
of visual function (including visual symptoms) and FAF
findings (global FAF abnormalities and patterns in Table 4;
FAF abnormalities by region in Table 5). BCVA worse than 20/
20 was significantly associated with global hyperautofluor-
escence and the perivascular pattern, but these associations
were not significant for the subpopulations of eyes with
visual impairment (BCVA of 20/50 or worse) or blindness
(BCVA of 20/200 or worse). Abnormal CS was associated with
global hypoautofluorescence (OR ¼ 3.20, P ¼ 0.02),
peripapillary confluent hypoautofluorescence (OR ¼ 2.31, P
¼ 0.04), and the descending tract pattern (OR ¼ 4.08, P ¼
0.006). Abnormal visual field (HVF-MD <3 dB) was
associated with global hypoautofluorescence, global hyper-
autofluorescence, and the perivascular, the peripapillary
confluent hypoautofluorescence, and the arcuate patterns
(Table 4). The arcuate pattern was also associated with
increased odds of abnormal color vision (C-index ‡ 1.78) and
abnormal CS (logCS < 1.5), but each of its associations were
of borderline significance (P values of 0.05–0.06). In general,
visual symptoms were more tightly related to FAF abnormal-
ities than other measures of visual function, particularly the
symptoms of poor color vision, poor contrast, nyctalopia, and
poor peripheral vision. Hypoautofluorescence was associated
with a greater number of visual symptoms than were other
FAF abnormalities.
As shown in Table 5, macular hypoautofluorescence, but
not hyperautofluorescence, was associated with BCVA 20/
25 and with visual impairment (20/50 or worse); extramac-
ular hypoautofluorescence was not associated with BCVA.
Abnormal CS and abnormal visual field were each associated
with both macular and extramacular hypoautofluorescence.
Abnormal color vision was associated only with macular
hypoautofluorescence. The symptoms of abnormal color
vision and poor contrast were each also associated with both
macular and extramacular hypoautofluorescence, although
some of the associations were weak. Controlling for
demographic factors, treatment, and intraocular inflammation
did not alter any of the statistically significant associations
between vision and the FAF findings listed in Table 5 (data not
shown).
In contrast to the relationships seen with other symptoms,
there were significantly reduced odds of having vibrating
vision in the presence of several FAF abnormalities (Tables 4
and 5). We also found a negative relationship between the
symptom of vibrating vision and duration of disease; those with
vibrating vision had a median duration of 2.6 years, whereas
those without the symptom had a median duration of 6.5 years
(P ¼ 0.0001).
DISCUSSION
FAF imaging has been used to study a variety of inflammatory
eye diseases, including multifocal choroiditis and panuveitis
syndrome, punctate inner choroidopathy, serpiginous choroid-
itis, multiple evanescent white dot syndrome, and Vogt-
Koyanagi-Harada disease.23–37 In many conditions, FAF imaging
reveals areas of disease activity that are more widespread than
would be suspected by other imaging techniques or by clinical
investigation, suggesting its potential value in the clinical
assessment of patients with these disorders.
With our large cohort, we confirmed that FAF abnormalities
are also widespread in eyes with BSCR. Peripapillary findings
are most common, consistent with the fact that clinical
birdshot lesions are most prevalent in the peripapillary area.7
A variety of FAF characteristics and patterns of FAF abnormal-
ities were seen in our cohort, and many were found to be
statistically related to other disease-related factors, including
intraocular inflammatory signs and measures of vision. No
single FAF finding was dominant in these relationships, and
further assessment, including longitudinal studies, will be
required to determine the clinical relevance of specific FAF
characteristics and patterns.
The most frequent FAF finding was peripapillary confluent
hypoautofluorescence, present in 122 (73%) eyes. Approxi-
mately half of eyes had abnormal macular FAF. Overall, these
observations are consistent with smaller and mostly retrospec-
tive studies of FAF in eyes with BSCR.2–4,38,39 Peripapillary
hypoautofluorescence was strongly related with age and
disease duration. Global hypoautofluorescence (i.e., present
in both the macula and extramacular region) was associated
longer disease duration (OR¼1.46, P < 0.001) and presence of
macular edema (OR ¼ 5.26, P < 0.001), suggesting that
hypoautofluorescence may be a marker for chronicity and
severity of BSCR.
We also categorized hypoautofluorescence by type (granu-
lar versus confluent) and anatomic location (macula versus
extramacular region) for additional, in-depth analyses. The
granular form seems to reflect a preconfluent loss of RPE cells
that can be observed before the development of confluent cell
loss, as has been described in other retinal disease.21,24 In
support of this assumption was the observation that study
participants with granular hypoautofluorescence had shorter
disease duration than those with confluent hypoautofluores-
cence. In addition to progression from granular to confluent
hypoautofluorescence, there was a suggestion of centripetal
progression of confluence toward the central macula.
In contrast to hypoautofluorescence, the clinical relevance
of hyperautofluorescence is less clear. In general, our data did
not demonstrate strong associations with hyperautofluores-
cence, although we did find it to be significantly related to
selected factors, including vitreous cells (OR¼ 2.14, P¼ 0.04)
and some measures of vision, most notably abnormal visual
field (both abnormal HVF-MD and the symptom of poor
peripheral vision). Increased autofluorescence can be seen
with RPE dysfunction. Lipofuscin has been shown to accumu-
late in experimental models of autoimmune uveitis, and
oxidative damage to various ocular tissues seems to play a
role in uveitic diseases.23,40,41 Taken together, the visualization
of lipofuscin accumulation in the RPE may reflect disease
activity, especially in the early stages. Alternatively, hyper-
autofluorescence may indicate unmasking of underlying RPE
autofluorescence by photoreceptor loss, and may indicate an
earlier form of visual dysfunction.
With regard to specific patterns of abnormal FAF, Koizumi et
al.2 described linear hypoautofluorescent streaks along the
retinal vessels in eyes with BSCR, and we observed a similar
perivascular pattern in over one-third of study participants.
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Women had a significantly higher risk of having this pattern of
FAF. As pointed out by Koizumi et al.,2 the perivascular pattern
is intriguing because major retinal vessels are located in the
superficial retina, far above the RPE. RPE dysfunction below
retinal vessels suggests a role for the retinal vasculature in
disease pathogenesis. Sheathing of retinal vessels is a well-
known, but not universal, finding in eyes with BSCR. Retinal
vascular sheathing was not significantly associated with the
perivascular pattern (Table 3); FAF imaging may be a more
sensitive tool for monitoring vascular involvement in future
studies of BSCR.
We also observed abnormal hypoautofluorescence in an
arcuate pattern at the posterior pole. In contrast to the
perivascular pattern, hypoautofluorescence in this pattern was
not necessarily in proximity to retinal vessels. This presenta-
tion has not been described previously as a specific FAF
pattern, but it was a frequent finding in our cohort (30% of
study participants; 26% of affected eyes). This arcuate pattern
was related to vitreous cells and to abnormalities in several
measures of visual function. Also, study participants who were
on immunomodulatory therapy had a lower risk for the arcuate
pattern. These associations suggest the importance of this
previous unreported pattern as a manifestation of BSCR.
Some eyes exhibited abnormal autofluorescence in a
descending tract pattern, as has been observed in patients
with central serous chorioretinopathy (CSC).21,42,43 Study
participants on immunomodulatory therapy had a lower risk
of the descending tract pattern, whereas those on systemic
corticosteroids had a higher risk. Corticosteroids have been
identified as a risk factor for CSC, which raises the possibility of
a common pathogenetic mechanism that could be investigated.
Although both choroidal findings, as reported in our
previous publication about this cohort,1 and FAF abnormalities
were related to signs of intraocular inflammation, we did not
find evidence of substantial, direct relationships between the
choroid and RPE in eyes with BSCR. This observation suggests
that the two sites may be affected independently during the
course of disease by different mechanisms, and thus, it may be
important to monitor each.
Unlike choroidal findings, various FAF abnormalities were
related to vision, as mentioned above. The strongest relation-
ships were found between hypoautofluorescence and abnor-
malities in BCVA, CS, and visual field. As shown in Table 5,
although both granular and confluent hypoautofluorescence
were associated with abnormal vision and visual symptoms,
confluent hypoautofluorescence had overall the greatest risk of
abnormal BCVA, visual impairment, and abnormal CS. As
would be expected, BCVA, a central visual function, was
associated only with macular FAF findings. The relationship
between macular hypoautofluorescence and reduced BCVA is
consistent with findings in eight individuals with BSCR
reported by Koizumi et al.2 Piffer et al.38 studied 39 individuals
with BSCR and also found that macular hypoautofluorescence
was linked to worse visual acuity, but in contrast to our study, it
was not affected by disease duration. The agreement between
Goldmann visual field (GVF) and autofluorescence was
analyzed in five individuals with BSCR by Jack et al.4 they
found a relatively small overlap, suggesting that GVF is
insensitive to anatomic RPE loss. Our data in a larger cohort
found several relationships between FAF findings and visual
field, using the automated Humphrey Field Analyzer. We
recognize that relationships between RPE and vision may be
influenced by retinal abnormalities associated with BSCR. The
relationships between RPE, retina, and vision will be explored
together in a future publication about this cohort.
Many clinicians recognize ‘‘vibrating vision’’ (a sensation
that the visual image is shaking) as a typical, albeit inconsistent,
symptom of BSCR. In contrast to the positive associations
between many other symptoms and FAF abnormalities, the
odds of having vibrating vision were significantly lower in
relation to FAF findings. It is possible that advanced disease, as
reflected by FAF abnormalities, damages those tissues or
processes responsible for vibrating vision, or masks the
symptom by compromising other visual functions necessary
to perceive it.
There are limitations to this study. As with any cross-
sectional analysis, we could not establish causality or temporal
relationships between autofluorescence findings and clinical
characteristics. Data were collected from different sites, using
different equipment, but images were acquired with a well-
defined, standardized protocol and were evaluated by two
readers independently. The autofluorescence systems used for
this study have no internal reference standards, which limits
the interpretation of the obtained FAF signal. Newer FAF
systems will provide quantitated AF, which improves the
determination of the signal. Our study definition of activity was
based on vitreous haze, which was not statistically associated
with any FAF finding; in contrast, the presence of vitreous cells
‡0.5þ was weakly related to several FAF patterns (Table 3).
The presence of cells may be a more sensitive predictor of RPE
damage than haze in people with BSCR. Furthermore, signs of
intraocular inflammation may not reflect all disease activity at
the tissue level. Therapeutic indications for treatment could
have biased relationships between clinical findings and
treatment. Because our institutions are all tertiary referral
centers, study participants may not be representative of all
individuals with BSCR.
Our study raises several issues that should be pursued in
future studies. The fact that there are statistical relationships
between FAF findings and signs of intraocular inflammation
and between FAF findings and visual function suggests that FAF
findings might be a marker that could help to guide treatment.
Such a determination will require a longitudinal study. The
possibility of direct drug effects on the RPE and FAF findings
should also be considered. Quantification of FAF signals, as
mentioned above, may provide additional information about
relationships. In addition, possible relationships between the
retinal vasculature and RPE can be explored further with
additional testing techniques (angiography, electrophysiologic
studies).
In conclusion, a number FAF abnormalities are widespread
in eyes with BSCR, and the relationship between these
abnormalities and intraocular inflammation suggests that the
RPE has a role in disease pathophysiology. Our study has also
shown that FAF abnormalities are markers of vision dysfunc-
tion. Although cross-sectional studies cannot confirm cause
and effect relationships, we found some evidence to support
the assumption that FAF abnormalities progress from granular
hypoautofluorescence to confluent hypoautofluorescence and
possibly that disease progresses centripetally toward the fovea,
raising the possibility that FAF imaging can be used clinically to
monitor patients for disease progression during treatment.
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